Ultra-low doses could bring costly cancer treatments to more patients in poorer countries

A lower-cost immunotherapy approach using ultra-low doses may extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to research presented at the American Society of Clinical Oncology annual meeting.